
RenovoRx (RNXT) Stock Forecast & Price Target
RenovoRx (RNXT) Analyst Ratings
Bulls say
RenovoRx Inc. is viewed positively due to its attractive current valuation and significant upside potential indicated by recent NPV analysis revisions. The company reported encouraging interim analysis results from its clinical studies, suggesting a 6-month potential improvement in median overall survival for patients treated with RenovoGem. Additionally, the planned commercialization of RenovoCath and anticipated positive clinical data in 2025 are expected to serve as strong catalysts for the company's stock performance.
Bears say
RenovoRx Inc reported a net loss of $2.4 million and an earnings per share (EPS) of $(0.10), slightly ahead of the analyst estimates but still indicative of ongoing financial challenges. The company operates in a high-risk sector, focusing on pancreatic cancer treatment, which has the lowest 5-year overall survival rate at 12%, underscoring significant unmet medical needs and poor patient outcomes. Despite potential growth prospects, the combination of persistent net losses and the daunting landscape of pancreatic cancer therapy presents substantial concerns regarding the company's financial sustainability and market position.
This aggregate rating is based on analysts' research of RenovoRx and is not a guaranteed prediction by Public.com or investment advice.
RenovoRx (RNXT) Analyst Forecast & Price Prediction
Start investing in RenovoRx (RNXT)
Order type
Buy in
Order amount
Est. shares
0 shares